Get the Stockscreener App
35.59
0.17%
0.06
After Hours:
35.64
0.05
+0.14%
Rapport Therapeutics Inc stock is traded at $35.59, with a volume of 164.33K.
It is up +0.17% in the last 24 hours and up +5.99% over the past month.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
See More
Previous Close:
$35.53
Open:
$35.88
24h Volume:
164.33K
Relative Volume:
0.50
Market Cap:
$1.70B
Revenue:
-
Net Income/Loss:
$-111.48M
P/E Ratio:
-12.42
EPS:
-2.865
Net Cash Flow:
$-88.09M
1W Performance:
+5.48%
1M Performance:
+5.99%
6M Performance:
+36.00%
1Y Performance:
+224.13%
1-Day Range:
$34.84
$36.65
1-Week Range:
$32.41
$36.65
52-Week Range:
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
35.59 | 1.70B | 0 | -111.48M | -88.09M | -2.865 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-02-26 | Initiated | Wells Fargo | Overweight |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
Rapport Therapeutics Insiders Added US$1.61m Of Stock To Their Holdings - Yahoo Finance
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Third Rock Ventures Sells 17 Million Dollars in Rapport Therapeutics - HarianBasis.co
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near - AOL.com
Bullish Rapport Therapeutics Insiders Loaded Up On US$1.61m Of Stock - 富途牛牛
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
Price-Driven Insight from (RAPP) for Rule-Based Strategy - Stock Traders Daily
Rapport Therapeutics prices $250M stock at $26 per share - MSN
RAPP Should I Buy - Intellectia AI
Rapport Therapeutics, Inc. ($RAPP) CEO 2025 Pay Revealed - Quiver Quantitative
BTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), Danaher (DHR) and Intuitive Surgical (ISRG) - The Globe and Mail
Rapport Therapeutics (RAPP) outlines 2026 vote, board structure and executive pay - Stock Titan
Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG - Moomoo
Rapport Therapeutics advances RAP-219 after strong Phase 2a data - The Globe and Mail
Rapport Therapeutics Reports Sustained Seizure Reduction With RAP-219 in Phase 2a Focal Onset Seizure Trial at 2026 AAN Meeting - Minichart
Wells Fargo Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Rapport Therapeutics CDO Yeleswaram Krishnaswamy sells $808,844 stock By Investing.com - Investing.com India
Third Rock Ventures sells $17.1m in Rapport Therapeutics stock - Investing.com UK
Rapport Therapeutics reports extended efficacy data for RAP-219 By Investing.com - Investing.com Australia
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Th - GuruFocus
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells 426,005 Shares of Stock - MarketBeat
Third Rock Ventures sells $17.1m in Rapport Therapeutics stock By Investing.com - Investing.com South Africa
RAPP Reports Positive Results from Phase 2a Trial Follow-Up - GuruFocus
Krishnaswamy Yeleswaram Sells 20,225 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics Presents Rap-219 Focal Onset Seizure Phase 2A Follow-Up Period Results - TradingView
Rapport Therapeutics CDO Yeleswaram Krishnaswamy sells $808,844 stock - Investing.com
Rapport Therapeutics reports extended efficacy data for RAP-219 - Investing.com
Rapport Therapeutics reports sustained seizure reductions, 22-day half-life for RAP-219 in Phase 2a follow-up - TradingView
Rapport Therapeutics (RAPP) posts durable RAP-219 seizure cuts and details late-stage plans - Stock Titan
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting - The Manila Times
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.2%Here's What Happened - MarketBeat
Rapport Therapeutics (RAPP) Stock Value Opportunity (On the Radar) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Is Rapport Therapeutics (RAPP) stock continuing its trend (Ticks Higher) 2026-04-18Public Sentiment - Xã Châu Thành
Rapport Therapeutics (NASDAQ:RAPP) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Brokered 10b5-1 sales listed for RAPP (NASDAQ: RAPP) - Stock Titan
[144] Rapport Therapeutics, Inc. SEC Filing - Stock Titan
(RAPP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 9,165 Shares of Stock - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 500 Shares - MarketBeat
Rapport Therapeutics Insider Sold Shares Worth $695,823, According to a Recent SEC Filing - marketscreener.com
Rapport Therapeutics (RAPP) CDO sells 19,865 shares under 10b5-1 plan - Stock Titan
10b5-1 insider sales reported for RAPP (NASDAQ: RAPP) in March–April 2026 - Stock Titan
What is the dividend outlook for Rapport Therapeutics (RAPP) Stock | Price at $34.13, Down 0.12%Expert Entry Points - Newser
Is Rapport Therapeutics Inc undervalued by DCF analysis2026 Pullbacks & Reliable Price Breakout Alerts - baoquankhu1.vn
How Investors May Respond To Rapport Therapeutics (RAPP) Phase 2a RAP-219 Data Spotlight At AAN 2026 - simplywall.st
Rapport Therapeutics Inc Stock (RAPP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):